Global Viral Vectors for Cell Therapy Market Research Report 2022: Demographic Trends, New Developments, Cell and Gene Therapy Advancements, Company Performance Trends, M&As
Dublin, Jan. 19, 2022 (GLOBE NEWSWIRE) -- The "Viral Vectors Market for Cell Therapy Market: Analysis and Opportunities" report has been added to ResearchAndMarkets.com's offering.
All market data are based on manufacturer sales to the end user and not retail pricing or reimbursement payments. Market data pertains to the world market at the manufacturers' level.
The base year for data was 2021 with forecast data provided for 2026. Compound annual growth rates (CAGRs) are provided for the 2021-2026 periods for each segment covered.
The forecasted market analysis for 2021-2026 is largely based on demographic trends, new developments, cell and gene therapy advancements, company performance trends, merger and acquisitions, and global expansion.
Viral vectors are useful tools used by molecular biologists to deliver genetic material into cells. The Viral Vectors Market Analysis and Opportunities report reveals that viral vectors comprise a rising market that is expected to continue to grow as usage increases and novel technologies enter the market.
Viral vectors are the most effective means of gene transfer to modify specific cells or alter the expression of therapeutic genes. The choice of viral vector depends on the efficiency of transgene expression, ease of production, safety, toxicity, and stability. Viral vector technology is used in gene therapy and vaccines. It is an exciting and interesting time to be involved in the viral vector industry.
Science is moving ahead and now the industry needs to industrialize and standardize the manufacturing and commercialization of products. The industry is moving in the direction of a standardized set-up and a closed automated system. This is especially true in gene therapy.
Consequently, gene therapy products are transforming the treatment of cancers and genetic diseases. Viral vectors do not cause disease since they have been modified by removing the genes involved in replication and are replaced with therapeutic genes. Viral vectors are genetically stable, non-toxic for host cells and safe to handle.
Viruses attack the host and introduce genetic material as part of the replication cycle. The genetic material contains basic instructions for the cell to reproduce, hijacking the body's normal production machinery to serve the needs of the virus. Thus, additional copies of the virus are produced leading to more cells becoming infected.
Then why use viruses for gene therapy? - because viruses could be good vehicles to transport good genes into the human cell. Scientists remove the genes in the virus that cause disease and replace them with genes encoding the desired effect.
Many gene therapy clinical trials rely on retroviruses or adenoviruses to deliver the desired gene. Other viruses used as vectors include adeno-associated viruses, lentiviruses, pox viruses, alphaviruses, and herpes viruses. These viruses differ in how well they transfer genes to the cells they recognize and are able to infect, and whether they alter the cell's DNA permanently or temporarily.
Viral vectors are defined by three components:
The protein capsid and/or envelope
The transgene of interest to produce the desired effect
The regulatory cassette - which is combined elements that control stable or transient somatic expression of the transgene
Key Topics Covered:
Chapter 1: Executive Summary
Overview
Scope And Methodology
Market Trends
Market Drivers And Limiters
Market Summary
Competitive Landscape
Chapter 2: Introduction to Viral Vectors
Overview
Types of Viral Vectors
Retrovirus
Adenovirus
HSV Virus
Chimeric Virus
Other
Disease Profiles in Viral Vector Markets
Cancer
Cardiovascular Disease
Selected Blood and Genetic Disorders
Infectious Diseases
Chapter 3: Market Trends
Population and Aging
Elderly Population
Gene Therapy and Viral Vector Use
Cancer and Viral Vector Use
Infectious Disease and Viral Vector Use
Transduction and Transfection
Transfection
Transduction
Competing Methods
Electroporation
Non-Viral
Transposons
Viral Vector Shortages
Covid-19 Platforms And Vaccines
Products in Development Utilizing Viral Vectors
Chapter 4: Market Analysis
Viral Vector Market By Vector Type
Viral Vector Market Share By Disease
Viral Vector Use By Application
Viral Vector Workflow Processing
Viral Vector Market By Region
Chapter 5: Competitors
Competitive Landscape
Alliances, Acquisitions And Collaborations
Expansion Of Manufacturing
Competitor Analysis
Chapter 6: Market Participant Profiles
4D Molecular Therapeutics, Inc. (4DMT)
ABL Inc
AGC Biologics
Agilent Technologies
Aldevron
Batavia Biosciences B.V.
Biovian Oy
Catapult Cell and Gene Therapy
Cevec Pharmaceuticals GmbH
Cobra Biologics
Cytiva Life Sciences
Finvector Oy
Fujifilm Diosynth Biotechnologies
Genezen
Horizon Discovery Ltd.
Lonza
Merck Kgaa/Millipore Sigma
Mirus Bio
Oxford Biomedica plc.
Regenxbio, Inc
Sanofi S.A.
Sirion Biotech
Spark Therapeutics, Inc
Takara Bio
Thermo Fisher Scientific
Uniqure N.V.
Vector Biolabs
Vigene Biosciences
Virocell Biologics
Virovek
Voyager Therapeutics
Waisman Biomanufacturing
Yposkesi
For more information about this report visit https://www.researchandmarkets.com/r/lperie
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900